Is LFMD or CSTL more profitable?

LifeMD has a net margin of 2.37% compared to Castle Biosciences' net margin of -3.78%. Castle Biosciences' return on equity of -2.77% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Castle Biosciences -3.78% -2.77% -2.30%

Does the media prefer LFMD or CSTL?

In the previous week, Castle Biosciences had 8 more articles in the media than LifeMD. MarketBeat recorded 11 mentions for Castle Biosciences and 3 mentions for LifeMD. LifeMD's average media sentiment score of 0.96 beat Castle Biosciences' score of 0.09 indicating that LifeMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LFMD or FLGT more profitable?

LifeMD has a net margin of 2.37% compared to Fulgent Genetics' net margin of -23.04%. Fulgent Genetics' return on equity of -3.24% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Fulgent Genetics -23.04% -3.24% -2.97%

Does the media prefer LFMD or FLGT?

In the previous week, Fulgent Genetics had 3 more articles in the media than LifeMD. MarketBeat recorded 6 mentions for Fulgent Genetics and 3 mentions for LifeMD. LifeMD's average media sentiment score of 0.96 beat Fulgent Genetics' score of 0.94 indicating that LifeMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TOI or LFMD?

In the previous week, Oncology Institute had 4 more articles in the media than LifeMD. MarketBeat recorded 7 mentions for Oncology Institute and 3 mentions for LifeMD. Oncology Institute's average media sentiment score of 1.60 beat LifeMD's score of 0.96 indicating that Oncology Institute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncology Institute 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive LifeMD 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MCTA or LFMD?

LifeMD has a consensus price target of $9.14, suggesting a potential upside of 152.22%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than Charming Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Charming Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LifeMD 2 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has higher earnings & valuation, MCTA or LFMD?

LifeMD has higher revenue and earnings than Charming Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Charming Medical N/A N/A N/A N/A N/A LifeMD $194.05M 0.90 $14.35M $0.05 72.50

Do analysts prefer LFMD or VMD?

LifeMD presently has a consensus target price of $9.14, indicating a potential upside of 152.22%. Given LifeMD's stronger consensus rating and higher possible upside, equities research analysts clearly believe LifeMD is more favorable than Viemed Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeMD 2 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.60 Viemed Healthcare 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, LFMD or VMD?

Viemed Healthcare has higher revenue and earnings than LifeMD. Viemed Healthcare is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 0.90 $14.35M $0.05 72.50 Viemed Healthcare $270.28M 1.67 $14.93M $0.37 31.78

Is LFMD or VMD more profitable?

Viemed Healthcare has a net margin of 5.20% compared to LifeMD's net margin of 2.37%. Viemed Healthcare's return on equity of 10.52% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Viemed Healthcare 5.20% 10.52% 7.60%

Does the media prefer LFMD or VMD?

In the previous week, Viemed Healthcare had 1 more articles in the media than LifeMD. MarketBeat recorded 4 mentions for Viemed Healthcare and 3 mentions for LifeMD. LifeMD's average media sentiment score of 0.96 beat Viemed Healthcare's score of 0.73 indicating that LifeMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viemed Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

LifeMD (LFMD) Competitors

$3.62 -0.02 (-0.41%)

Closing price 03:59 PM Eastern

Extended Trading

$3.62 -0.01 (-0.28%)

As of 05:14 PM Eastern

Compare

LFMD vs. CSTL, FLGT, TOI, MCTA, and VMD

Should you buy LifeMD stock or one of its competitors? MarketBeat compares LifeMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LifeMD include Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Oncology Institute (TOI), Charming Medical (MCTA), and Viemed Healthcare (VMD). These companies are all part of the "healthcare" industry.

How does LifeMD compare to Castle Biosciences?

LifeMD (NASDAQ:LFMD) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

LifeMD has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

In the previous week, Castle Biosciences had 8 more articles in the media than LifeMD. MarketBeat recorded 11 mentions for Castle Biosciences and 3 mentions for LifeMD. LifeMD's average media sentiment score of 0.96 beat Castle Biosciences' score of 0.09 indicating that LifeMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LifeMD has a net margin of 2.37% compared to Castle Biosciences' net margin of -3.78%. Castle Biosciences' return on equity of -2.77% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Castle Biosciences	-3.78%	-2.77%	-2.30%

35.5% of LifeMD shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 17.2% of LifeMD shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

LifeMD has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.90	$14.35M	$0.05	72.50
Castle Biosciences	$344.23M	2.36	-$24.16M	-$0.44	N/A

LifeMD presently has a consensus target price of $9.14, suggesting a potential upside of 152.22%. Castle Biosciences has a consensus target price of $42.43, suggesting a potential upside of 58.37%. Given LifeMD's higher probable upside, equities analysts plainly believe LifeMD is more favorable than Castle Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

LifeMD beats Castle Biosciences on 9 of the 17 factors compared between the two stocks.

How does LifeMD compare to Fulgent Genetics?

LifeMD (NASDAQ:LFMD) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

LifeMD currently has a consensus price target of $9.14, suggesting a potential upside of 152.22%. Fulgent Genetics has a consensus price target of $27.00, suggesting a potential upside of 33.60%. Given LifeMD's stronger consensus rating and higher possible upside, equities analysts clearly believe LifeMD is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

LifeMD has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.90	$14.35M	$0.05	72.50
Fulgent Genetics	$322.67M	1.78	-$60.51M	-$2.39	N/A

35.5% of LifeMD shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 17.2% of LifeMD shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Fulgent Genetics had 3 more articles in the media than LifeMD. MarketBeat recorded 6 mentions for Fulgent Genetics and 3 mentions for LifeMD. LifeMD's average media sentiment score of 0.96 beat Fulgent Genetics' score of 0.94 indicating that LifeMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeMD has a net margin of 2.37% compared to Fulgent Genetics' net margin of -23.04%. Fulgent Genetics' return on equity of -3.24% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

LifeMD has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Summary

LifeMD beats Fulgent Genetics on 9 of the 16 factors compared between the two stocks.

How does LifeMD compare to Oncology Institute?

Oncology Institute (NASDAQ:TOI) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by company insiders. Comparatively, 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

LifeMD has lower revenue, but higher earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73M	1.00	-$60.61M	-$0.37	N/A
LifeMD	$194.05M	0.90	$14.35M	$0.05	72.50

Oncology Institute currently has a consensus target price of $8.50, suggesting a potential upside of 67.65%. LifeMD has a consensus target price of $9.14, suggesting a potential upside of 152.22%. Given LifeMD's higher probable upside, analysts plainly believe LifeMD is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Oncology Institute had 4 more articles in the media than LifeMD. MarketBeat recorded 7 mentions for Oncology Institute and 3 mentions for LifeMD. Oncology Institute's average media sentiment score of 1.60 beat LifeMD's score of 0.96 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncology Institute	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
LifeMD	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeMD has a net margin of 2.37% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
LifeMD	2.37%	-150.88%	-22.59%

Oncology Institute has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, LifeMD has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

Summary

LifeMD beats Oncology Institute on 9 of the 15 factors compared between the two stocks.

How does LifeMD compare to Charming Medical?

Charming Medical (NASDAQ:MCTA) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

In the previous week, LifeMD had 2 more articles in the media than Charming Medical. MarketBeat recorded 3 mentions for LifeMD and 1 mentions for Charming Medical. Charming Medical's average media sentiment score of 1.92 beat LifeMD's score of 0.96 indicating that Charming Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Charming Medical	Very Positive
LifeMD	Positive

LifeMD has a net margin of 2.37% compared to Charming Medical's net margin of 0.00%. Charming Medical's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charming Medical	N/A	N/A	N/A
LifeMD	2.37%	-150.88%	-22.59%

35.5% of LifeMD shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

LifeMD has a consensus price target of $9.14, suggesting a potential upside of 152.22%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than Charming Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charming Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

LifeMD has higher revenue and earnings than Charming Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charming Medical	N/A	N/A	N/A	N/A	N/A
LifeMD	$194.05M	0.90	$14.35M	$0.05	72.50

Summary

LifeMD beats Charming Medical on 8 of the 11 factors compared between the two stocks.

How does LifeMD compare to Viemed Healthcare?

LifeMD (NASDAQ:LFMD) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

LifeMD presently has a consensus target price of $9.14, indicating a potential upside of 152.22%. Given LifeMD's stronger consensus rating and higher possible upside, equities research analysts clearly believe LifeMD is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Viemed Healthcare has higher revenue and earnings than LifeMD. Viemed Healthcare is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.90	$14.35M	$0.05	72.50
Viemed Healthcare	$270.28M	1.67	$14.93M	$0.37	31.78

LifeMD has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

In the previous week, Viemed Healthcare had 1 more articles in the media than LifeMD. MarketBeat recorded 4 mentions for Viemed Healthcare and 3 mentions for LifeMD. LifeMD's average media sentiment score of 0.96 beat Viemed Healthcare's score of 0.73 indicating that LifeMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viemed Healthcare	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Viemed Healthcare has a net margin of 5.20% compared to LifeMD's net margin of 2.37%. Viemed Healthcare's return on equity of 10.52% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Viemed Healthcare	5.20%	10.52%	7.60%

35.5% of LifeMD shares are held by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are held by institutional investors. 17.2% of LifeMD shares are held by company insiders. Comparatively, 20.6% of Viemed Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Viemed Healthcare beats LifeMD on 10 of the 16 factors compared between the two stocks.

Get LifeMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFMD vs. The Competition

Export

Metric	LifeMD	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$175.31M	$9.63B	$6.96B	$12.28B
Dividend Yield	N/A	1.58%	2.65%	8.54%
P/E Ratio	72.51	25.78	27.62	23.71
Price / Sales	0.90	18.81	525.54	91.62
Price / Cash	N/A	136.45	51.57	59.34
Price / Book	7.55	6.13	10.06	5.85
Net Income	$14.35M	$179.69M	$3.60B	$336.53M
7 Day Performance	-6.33%	-0.80%	-0.28%	-0.45%
1 Month Performance	-11.93%	-1.90%	-3.31%	-4.96%
1 Year Performance	-64.07%	13.83%	22.59%	16.74%

LifeMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFMD LifeMD	2.9324 of 5 stars	$3.63 -0.4%	$9.14 +152.2%	-64.3%	$175.31M	$194.05M	72.51	230	News Coverage Upcoming Earnings
CSTL Castle Biosciences	3.6881 of 5 stars	$23.90 -1.1%	$42.43 +77.5%	+50.7%	$732.77M	$344.23M	N/A	540	News Coverage Earnings Report Insider Trade
FLGT Fulgent Genetics	2.3522 of 5 stars	$19.61 -2.7%	$27.00 +37.7%	+11.7%	$572.56M	$322.67M	N/A	1,315
TOI Oncology Institute	4.0546 of 5 stars	$5.50 +2.8%	$8.40 +52.7%	+31.8%	$528.79M	$502.73M	N/A	660	Positive News
MCTA Charming Medical	N/A	$29.36 0.0%	N/A	N/A	$497.21M	N/A	N/A	49	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFMD) was last updated on 7/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeMD (LFMD) Competitors

LFMD vs. CSTL, FLGT, TOI, MCTA, and VMD

How does LifeMD compare to Castle Biosciences?

Summary

How does LifeMD compare to Fulgent Genetics?

Summary

How does LifeMD compare to Oncology Institute?

Summary

How does LifeMD compare to Charming Medical?

Summary

How does LifeMD compare to Viemed Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LifeMD (LFMD) Competitors

LFMD vs. CSTL, FLGT, TOI, MCTA, and VMD

How does LifeMD compare to Castle Biosciences?

Which has more risk & volatility, LFMD or CSTL?

Does the media prefer LFMD or CSTL?

Is LFMD or CSTL more profitable?

Do institutionals & insiders have more ownership in LFMD or CSTL?

Which has higher earnings and valuation, LFMD or CSTL?

Do analysts prefer LFMD or CSTL?

Summary

How does LifeMD compare to Fulgent Genetics?

Do analysts rate LFMD or FLGT?

Which has preferable valuation and earnings, LFMD or FLGT?

Do institutionals and insiders have more ownership in LFMD or FLGT?

Does the media prefer LFMD or FLGT?

Is LFMD or FLGT more profitable?

Which has more risk and volatility, LFMD or FLGT?

Summary

How does LifeMD compare to Oncology Institute?

Do insiders and institutionals hold more shares of TOI or LFMD?

Which has better valuation and earnings, TOI or LFMD?

Do analysts recommend TOI or LFMD?

Does the media favor TOI or LFMD?

Is TOI or LFMD more profitable?

Which has more volatility & risk, TOI or LFMD?

Summary

How does LifeMD compare to Charming Medical?

Does the media prefer MCTA or LFMD?

Is MCTA or LFMD more profitable?

Do insiders & institutionals hold more shares of MCTA or LFMD?

Do analysts recommend MCTA or LFMD?

Which has higher earnings & valuation, MCTA or LFMD?

Summary

How does LifeMD compare to Viemed Healthcare?

Do analysts prefer LFMD or VMD?

Which has better earnings and valuation, LFMD or VMD?

Which has more volatility and risk, LFMD or VMD?

Does the media prefer LFMD or VMD?

Is LFMD or VMD more profitable?

Do institutionals and insiders believe in LFMD or VMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools